Galli G, De Toma A, Pagani F, et al. - Using multivariate analyses with the Cox model, researchers assessed the efficacy and safety of immunotherapy (IO) in elderly patients with Non-Small Cell Lung Cancer in this study including patients < 70 year-old, 70-79 year-old, ≥ 80 year-old. They reviewed 290 cases, with a median age of 67 (range: 29-89), selected from their institution. Patients aged < 70, 70-79 and ≥ 80 year-old were 180, 94 and 16, respectively. Performance status (PS), the number of metastatic sites and IO line were identified as the only variables influencing the outcome. Findings revealed no link of advanced age with reduced efficacy of IO in this case series. Even among the eldest patients, no toxicity concern was identified. Considering Immune Checkpoint Inhibitors was recommended regardless of age, provided an optimal PS at baseline. IO is usually the only treatment option applicable to these cases taking the toxicity of chemotherapy into account.